<- Go home

Added to YB: 2020-12-15

Pitch date: 2020-12-15

INVA [bullish]

Innoviva, Inc.

+88.78%

current return

Author Info

No bio for this author

Company Info

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.

Market Cap

$1.7B

Pitch Price

$11.76

Price Target

N/A

Dividend

N/A

EV/EBITDA

7.67

P/E

15.34

EV/Sales

3.96

Sector

Pharmaceuticals

Category

N/A

Show full summary:
INNOVIVA INC INVA

A summary for this pitch has not been created yet.

Read full article (0 min)